COLCHICINE FOR THE PREVENTION OF VASCULAR EVENTS AFTER AN ACUTE INTRACEREBRAL HEMORRHAGE (COVASC-ICH)

Registry ID

NCT05159219 (COVASC-ICH)

Source registry

HEALTH_CANADA

Status

Closed

Study type

INTERVENTIONAL

Sponsor

HAMILTON HEALTH SCIENCES CORPORATION

Start date

2022-04-01

Completion date

2025-02-11

Last update

2022-02-15

Conditions

• INTRACEREBAL HEMORRAGE
• MAJOR CARDIOVASCULAR EVENTS

Related clinical trials

• A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MK-0616 IN REDUCING MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PARTICIPANTS AT HIGH CARDIOVASCULAR RISK
• EDOXABAN FOR INTRACRANIAL HEMORRHAGE SURVIVORS WITH ATRIAL FIBRILLATION
• A DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED, MULTICENTER STUDY TO EVALUATE THE IMPACT OF EVOLOCUMAB ON MAJOR CARDIOVASCULAR EVENTS IN PATIENTS AT HIGH CARDIOVASCULAR RISK WITHOUT PRIOR MYOCARDIAL INFARCTION OR STROKE
• NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS FOR STROKE PREVENTION IN PATIENTS WITH ATRIAL FIBRILLATION AND PREVIOUS INTRACEREBRAL HEMORRHAGE STUDY
• INFLUENZA VACCINE TO EFFECTIVELY STOP CARDIO THORACIC EVENTS AND DECOMPENSATED HEART FAILURE (INVESTED)
• A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY AND DETERMINE THE MAXIMUM TOLERATED DOSE OF PF-05230907 IN SUBJECTS WITH INTRACEREBRAL HEMORRHAGE (ICH)

View on source registry